ALK-positive advanced non-small cell lung cancer patient with poor performance status - case report

Abstract

Poor performance status (PS) of the patient is one of the negative prognostic factors in the treatment of non-smaii cell lung cancer. Patients are usually excluded from clinical trial recruitment due to poor PS.

The available data concerning these patients are therefore mostly retrospective and "real world" The presented case report describes an individual who despite his initial borderline performance status benefits significantly from targeted therapy.

Keywords

• lung cancer
• performance status
• a Lectinib